Maja is part of US research that could help local authorities approve the BioNTech-Pfizer mRNA vaccine for children under 12. On Tuesday (October 26, 2021), the US Food and Drug Administration (FDA) will discuss the study results and is expecte to decide on vaccine approval soon.
This study shows good effectiveness.
The researchers tested the vaccine on 2,268 The Covid Vaccine For Children between the ages of 5 and 11. Approximately the same number of children received a placebo. After the study, the developers said they were confident that their vaccine would be safe and effective of children in this age group when the dose was reduce.
Children under 11 years of age receive about one-third of the dose that adults receive. This vaccine is only approve from use in children 12 years of age and older at the time of writing. BioNTech-Pfizer seeks approval in the US and EU, where the European Medicines Agency (EMA) made this decision. The EMA said it would decide in the coming months. Further applications for approval were produce worldwide.
Get it faster or wait?
“I support children under the age of 12 being vaccinate,” Kawsar Talaat said in an interview with DW. Kawsar Talaat is Associate Professor of International Health at the Johns Hopkins Bloomberg School of Public Health in the United States. Jakob Armann, a pediatrician in Germany, is now more cautious. To DW, Armand said that children with comorbidities should be vaccinate, “for example, if the child has trisomy 21”.
“I will wait until we have more data and I can see rare side effects like myocarditis. And then call out who will benefit from the vaccine and who will not,” he said.
Is the research enough?
Armann said the BioNTech-Pfizer study involved too few people for the public to launch a mass vaccination program confidently. For example, says Armann, there is evidence that some young men and boys can develop myocarditis, an inflammation of the heart muscle.
Children’s immune systems are activate quickly.
There’s another reason why some experts advise working slowly: Some children infected with COVID-19 experience severe cases. The infection often feels like a mild cold, they say.
The human immune system uses receptors that recognize patterns – like the shape of a virus – to protect the body from viral attack, Roland Isles said in an interview with DW. But these receptors must be activate: “Once activated, they trigger the production of interferon. Which is mainline of defense against any viral infection,” says Ayles. Head of the Digital Health department at Charité in Berlin. “And we found that compared to adults, children’s immune systems [are very good at activating these receptors,” he said.
School as a super public place
But Isles is not against vaccinating children because even if their infection is milder, they can still pass the virus on to others. The past year has shown some evidence from this in Germany. Even when and where overall morbidity has increased relatively slowly, schools can sometimes become quite mundane. Sitting close to dozens of unvaccinated children can lead to higher morbidity. For example, there is a weekly morbidity rate of 500 per 100,000 inhabitants in some German municipalities.
Vaccines don’t just protect you.
Talaat says vaccinating children increase herd immunity. This is a global goal – and a way to stop the virus from spreading once and for all. In addition, Talaat said, “COVID is affecting [children’s] lives in terms of ostracism, quarantine, inability to go to school, inability to carry out their normal activities, and so on. The best way to get his life back to normal is to vaccinate him. This will be one way to fulfill the dream of 10-year-old Maya and all her friends for a great night out.
Jigar Joshi, widely famous as Jigar Saraswat is an Indian content writer, Author, Blogger, Senior Editor working from 2015-16 in this vast field of Digital Marketing, PR, Content marketing. He has been providing Content writing services like Article writing, Press release writing, Blog writing, Website writing services etc for many years.